#Leusm
LightNews LightNews
hematologyadvisor.bsky.social
A review of #machinelearning models developed to support the management of chronic #lymphocyticLeukemia have demonstrated positive outcomes, including accurate diagnosis and improved work flow.

https://bit.ly/3HQxIqV

#lymsm #leusm
Machine Learning Models May Improve CLL Diagnosis and Management
Researchers determined machine learning models developed to support the management of CLL have demonstrated positive outcomes.
bit.ly
September 18, 2025 at 7:30 PM
drmiguelperales.bsky.social
No surprise running into @penncancer.bsky.social @bllphd.bsky.social at the #ASH24 #CARTcells for AML session #leusm
December 8, 2024 at 1:20 AM
onclive.bsky.social
Optimizing Treatment Sequences Remains Key in CLL/SLL
@ash-hematology.bsky.social #leusm #ASH24 #oncology #MedEd
www.onclive.com/view/optimiz...
Optimizing Treatment Sequences Remains Key in CLL/SLL
Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.
www.onclive.com
December 12, 2024 at 4:55 PM
hemedoc.bsky.social
#tandem25 #leusm Dipersio: N=25 patients (24 AML, 1 MDS; mostly adverse risk; 33% TP53m) received Trem-cel after MAC then received GO monthly starting +60days for up to 8 cycles. 16 infused w Trem-cel. Quick engraftment. Minimal GVHD wo ppx (graft is TCD).
February 15, 2025 at 9:53 PM
ash.hematology.org
📅 Free Webinar Tomorrow!

Explore single-cell technologies in hematology at our webinar: Single Cell Multi-omics in Precision Medicine.

🔗 Register now: ow.ly/rNwW50UPGyp

#Hematology #PrecisionMedicine #Leusm #MMsm #HemeSky #BloodSky
February 10, 2025 at 7:56 PM
drhkantarjian.bsky.social
Updated results of our frontline trial of FLAG-IDA+VEN, showing CRc in 95% of newly diagnosed #AML. Responses were seen across all ELN22 risk groups, w/ 90% MRD neg. In RR AML, 79% first salvage & TP53wt attained CRc.
@mdanderson.bsky.social
rdcu.be/ebcvm
#leusm
February 25, 2025 at 7:36 PM
hemedoc.bsky.social
#ASH24 #leusm Heuser: alloHCT outcomes for MRD+ pre-HCT generally poor but MAC may be able to overcome (some) MRD positivity. Giving additional intensive chemo where possible (esp NPM1+ which tend to be chemo sensitive) before alloHCT likely useful.
December 7, 2024 at 6:19 PM
onclive.bsky.social
The @fda.gov Approves Treosulfan for alloHCT Conditioning in AML and MDS #leusm #mpnsm #oncology
www.onclive.com/view/fda-app...
FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS
The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.
www.onclive.com
January 24, 2025 at 9:18 PM
majorajay.bsky.social
Poster #ASH24: again, figures speak for themselves. Early ibrutinib in asymptomatic CLL does not improve global QOL and results in worsening of bruising versus placebo. Watch & wait remains the standard of care. #lymsm #leusm #MajorPROsASH
December 7, 2024 at 8:58 PM
drhkantarjian.bsky.social
New in Leukemia Journal: Outcomes in intensively treated KMT2Ar #AML have improved over time. But low-intensity therapies still show poor results — highlighting the urgent need to explore menin inhibitors
www.nature.com/articles/s41...
#leusm
@mdanderson.bsky.social
May 13, 2025 at 5:40 PM
cancertherapyadv.bsky.social
The recent EHA 2025 Congress showcased novel combinations for MDS and AML as well as a novel formulation of a drug for B-ALL: an opinion piece by @ashkishtaagri.bsky.social of @vanderbilt.edu shorturl.at/RkY2M #EHA2025 #leusm #mdssm
Opinion: Top Studies From EHA 2025
Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.
shorturl.at
July 7, 2025 at 4:07 PM
onclive.bsky.social
🚨 June was a blockbuster month for oncology drug approvals. 🚨

🔐 Sign up to get the full story 📘 on the @US_FDA approvals changing clinical practice: www.onclive.com/view/onclive...

#RegulatoryRundown #oncology #pcsm #lcsm #lymsm #leusm
July 10, 2025 at 4:11 PM
hemedoc.bsky.social
#ASCO25 #leusm Desai: lower dose PTCy (70) assoc with slightly faster engraftment and no diff in GVHD incidence vs standard (100).
May 30, 2025 at 6:24 PM
onclive.bsky.social
Quizartinib Plus Chemotherapy Shows Strong Activity in FLT3-ITD–Positive, NPM1-Mutated AML #EHA25 #leusm www.onclive.com/view/quizart...
Quizartinib Plus Chemotherapy Shows Strong Activity in FLT3-ITD–Positive, NPM1-Mutated AML
FLT3-ITD positivity plus mutations in NPM1 and epigenetic regulatory genes led to heightened efficacy of quizartinib plus chemotherapy in newly diagnosed AML.
www.onclive.com
June 26, 2025 at 1:44 PM
vjhemonc.bsky.social
Watch our recent interview with Jae Park of @mskcancercenter.bsky.social to hear about the long-term data with obe-cel in ALL & its potential to serve as a standalone treatment for adult R/R B-ALL.

Click here:

👉 buff.ly/inx0gbp

#ALLsm #Leusm #Leukemia #CTSM #CARTCell #ImmunoOnc #HemOnc
August 1, 2025 at 4:42 PM
onclive.bsky.social
Emerging Data Continue to Shape the Role of Blinatumomab in Acute Lymphoblastic Leukemia #leusm #oncology www.onclive.com/view/emergin...
Emerging Data Continue to Shape the Role of Blinatumomab in Acute Lymphoblastic Leukemia
Adam Duvall, MD, MPH, spotlights new research further elucidating the role of blinatumomab in the acute lymphoblastic leukemia treatment paradigm.
www.onclive.com
February 6, 2025 at 10:04 PM
hemedoc.bsky.social
#tandem25 #leusm Chen: Gilteritinib did not show same benefit across all FLT3pos, but benefited those who enter into allo MRD pos. Any level of AML pre-allo MRD conveyed relapse risk.
February 14, 2025 at 9:37 PM
hemedoc.bsky.social
#tandem25 #leusm Zeiser: similarly, some AML mutations are assoc with incr expression of TIM3 which inhibits T cell responses. Anti-TIM3 mAb (sabatolimab) being investigated in myeloid malignancies.
February 14, 2025 at 8:57 PM
hemedoc.bsky.social
#tandem25 #leusm Zeiser: some mutations, eg, in c-kit, increase MDM2 expression
February 14, 2025 at 8:53 PM
onclive.bsky.social
AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML
@fda.gov #leusm #hematology
www.onclive.com/view/autx-70...
AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML
The FDA has granted the novel, oral KAT2A/B degrader AUTX-703 fast track designation for the treatment of patients with relapsed/refractory AML.
www.onclive.com
February 24, 2025 at 5:53 PM
hemedoc.bsky.social
#ASH24 #leusm Plesa: a standardized approach to detect MRD by LAIP/DfN (leuk assoc immunophenotype or diff from normal) and presumed LSC (34+38-) in marrow was estabd across France. 315 pts on BIG-1 AML trial evaluated using these methods at baseline, EOI (MRD1), & after C2 (either ind2/cons1; MRD2)
December 7, 2024 at 11:49 PM
hemedoc.bsky.social
#ASH24 #leusm Jacoby: failure to clear leuk assoc mutations (LAMS) after induction assoc with decre RFS. This study assigned this with clearance (
December 7, 2024 at 10:33 PM
hemedoc.bsky.social
#ASH24 #leusm Radich: some “MRD+” may not relapse — or, if MRD assessment is detecting CHIP mutations, so interpretation of genetic MRD assessments needed rather than accepting any persistence of mutations in CR as evidence of disease.
December 7, 2024 at 5:45 PM
vjhemonc.bsky.social
What is the current role of T-cell engagers and CARs in myeloid malignancies?🩸

Find out by watching our exclusive expert discussion from #iwCART25 with David Sallman, Marion Subklewe, Jae Park, & Andrew Kuykendall here:

👉 buff.ly/mQBv32R

#AMLsm #Leusm #MPNsm #ImmunoOnc #HemeSky #BloodSky
May 15, 2025 at 3:04 PM
vjhemonc.bsky.social
Check out this week's podcast!🎙️

Featuring Marlise Luskin, Nicole LeBoeuf, and Shai Shimony, who share insights into BPDCN from a hematology and dermatology perspective.

🎧 Listen here: https://buff.ly/3ZxE0S6

#HemOnc #Leusm #MPNsm
December 2, 2024 at 12:35 PM